for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Torrent Pharmaceuticals Ltd

TORP.NS

Latest Trade

2,657.65INR

Change

-25.85(-0.96%)

Volume

815,402

Today's Range

2,620.30

 - 

2,718.00

52 Week Range

2,311.10

 - 

3,298.50

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
2,683.50
Open
2,705.00
Volume
815,402
3M AVG Volume
5.65
Today's High
2,718.00
Today's Low
2,620.30
52 Week High
3,298.50
52 Week Low
2,311.10
Shares Out (MIL)
170.00
Market Cap (MIL)
454,109.20
Forward P/E
36.93
Dividend (Yield %)
1.49

Next Event

Dividend For TORP.NS - 25.0000 INR

Latest Developments

More

India's Torrent Pharmaceuticals Dec-Quarter Consol Net Profit Falls

Torrent Pharma Says Voluntarily Recalled 1 Batch Of Telmisartan & Hydrochlorothiazide Tablets From U.S. Market

Torrent Pharma Issues Corporate Guarantee To MUFG Bank For Credit Facility Availed By Unit

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Limited is engaged in the manufacture and sale of branded, as well as unbranded generic pharmaceutical products. The Company operates in the therapeutic areas of cardiovascular (CV), central nervous system (CNS), gastrointestinal, diabetology, anti-infective, anti-diabetics and pain management segments. The Company offers products in various categories, including tablets, capsule and parenteral. Its geographical segments include India and outside India. It manufactures various active pharmaceutical ingredients (APIs), such as Nicorandil, Risperidone, Venlafaxine Hydrochloride, Ropinarole Hydrochloride, Duloxetine Hydrochloride, Ormeloxifen Hydrochloride, Nebivolol Hydrochloride, Lamotrigine and Sertraline Hydrochloride. The Company's subsidiaries include Heumann Pharma GmbH & Co., Torrent Pharma GmbH, Heunet Pharma GmbH, Norispharm GmbH, Torrent Pharma (Thailand) Co. Ltd., Torrent Pharma S.R.L., Aptil Pharma Limited and Laboratories Torrent Malaysia Sdn. Bhd.

Industry

Biotechnology & Drugs

Contact Info

Torrent House, Off. Ashram Road

380009

India

+91.79.26599000

http://www.torrentpharma.com/

Executive Leadership

Samir Mehta

Executive Chairman of the Board

Sudhir Mehta

Chairman Emeritus

Sudhir Menon

Chief Financial Officer

Mahesh Agrawal

Vice President - Legal, Company Secretary

Jinesh Shah

Additional Whole-time Director, Director (Operations)

Key Stats

2.58 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

76.7K

2020

79.4K

2021

80.1K

2022(E)

85.6K
EPS (INR)

2019

42.450

2020

60.550

2021

73.980

2022(E)

72.922
Price To Earnings (TTM)
37.24
Price To Sales (TTM)
5.46
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
24.11
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's Torrent Pharmaceuticals Posts March-Quarter Consol Net Profit

* MARCH-QUARTER CONSOL NET PROFIT 3.14 BILLION RUPEES VERSUS LOSS OF 1.52 BILLION RUPEES YEAR AGO

BRIEF-Torrent Pharmaceuticals Issues NCDs On Private Placement For 2 Bln Rupees

* TORRENT PHARMACEUTICALS -ISSUED NCDS ON PRIVATE PLACEMENT BASIS FOR AN AMOUNT OF 2 BILLION RUPEES Source text for Eikon: Further company coverage:

BRIEF-Torrent Pharmaceuticals Issues NCDs On Private Placement Basis For 1.95 Bln Rupees

* ISSUED NCDS ON PRIVATE PLACEMENT BASIS FOR AMOUNT OF 1.95 BILLION RUPEES Source text for Eikon: Further company coverage:

BRIEF-Torrent Pharmaceuticals Approves Interim Dividend Of 32 Rupees Per Share

* TORRENT PHARMACEUTICALS -APPROVED INTERIM DIVIDEND OF 32 RUPEES PER SHARE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up